|
Sign In to gain access to subscriptions and/or personal tools.
|
CSF APPs and Phosphorylated Tau Protein Levels in Mild Cognitive Impairment and Dementia of Alzheimers Type
Andreas Fellgiebel, MD*,
Elzbieta Kojro,
Matthias J. Muller,
Armin Scheurich,
Lutz G. Schmidt,
and
Falk Fahrenholz
Johannes Gutenberg University Mainz
* To whom correspondence should be addressed. E-mail: fellgiebel{at}psychiatrie.klinik.uni-mainz.de.
 |
Abstract |
|---|
We exploratively measured APPs , a secreted fragment of the non-amyloidogenic cleavage of amyloid precursor protein via a-secretase, and tau protein phosphorylated at threonine 181 (ptau) in the cerebrospinal fluid of 10 patients with mild cognitive impairment, 20 patients with dementia of Alzheimers type, and 10 controls. Cerebrospinal fluid APPs and ptau levels were correlated with cognitive performance. Ptau levels were significantly elevated in mild cognitive impairment and in patients with dementia of Alzheimers type, APPs levels were significantly reduced in patients with dementia of Alzheimers type compared to the controls. APPs levels were associated with Mini Mental State Examination total scores but not with Delayed Verbal Recall Test performance. Vice versa, ptau levels correlated only with Delayed Verbal Recall Test in patients with dementia of Alzheimers type or mild cognitive impairment. Both, an increase in ptau levels and a decrease in cerebrospinal fluid APPs , seem to refer to relevant but functionally different processes in the development of mild cognitive impairment and dementia of Alzheimers type.
First published on December 10, 2008, doi:10.1177/0891988708327810
Journal of Geriatric Psychiatry and Neurology 2009;22:3.
A more recent version of this article appeared on March 1, 2009

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|